Právní předpis byl sestaven k datu 19.09.2014.
Zobrazené znění právního předpisu je účinné od 20.12.2013 do 19.09.2014.
98
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx zahraničních xxxx x. 58/2007 Xx. x. x. x x. 46/2008 Sb. x. x. a xxxxxxxxx xxxxxxx Ministerstva xxxxxxxxxxxx xxxx x. 97/2012 Xx. x. x. x Xxxxxxxxxxx xxxxxx proti dopingu xx xxxxxx
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, že xxx 12. xxxxxxxxx 2012 xxxx xxxxxxxxx ředitelkou XXXXXX oznámeno xxxxxxxxx xxxxxx xxxxx Přílohy X - Xxxxxxx xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx dopingu ve xxxxxx1).
X novým xxxxxx Přílohy I xxxxxxxx souhlas Xxxxxxxxx Xxxxx xxxxxxxxx.
Xxxx xxxxx Xxxxxxx I xxxxxxxxx x xxxxxxxx x xxxxxxx x xxxxxxx 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2013 x xxxxx dnem xxxxxxxxx v platnost x pro Xxxxxx xxxxxxxxx. Dnem xxxxxx xxxxxx xxxxx Xxxxxxx X x xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx X Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx xxxxxx xx 1. xxxxx 2012 a xxxxxxxxx xxx č. 97/2012 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx X x xxxx xxxxxxx xx xxxxxxx jazyka xx xxxxxxxxx xxxxxxxx.
1) Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx xxxxxxx xxx 19. xxxxx 2005 x Xxxxxx xxxx xxxxxxxxx pod č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
XXXXXXX I
XXXXXX XXXXXXXXXX XXXXX X METOD XXXXXXX XXX XXX 2013
XXXXXXX ANTIDOPINGOVÝ XXXXX
Xxxxxx xx 1. xxxxx 2013
Podle xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx látek xx skupin S1, X2, X4.4, X4.5 x X6(x) a Xxxxxxxxxx metod X1, X2 x X3.
| &xxxx;
XXXXX X METODY XXXXXXXX XXXXX
(XXX SOUTĚŽI X XXXX SOUTĚŽ)
|
XXXXXXXX LÁTKY
S0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx látka, která xxxx zahrnuta x xxxxxxxxxxxxx xxxxxxx Seznamu x není xxxxxxxx xxxxxxxxx pro humánní xxxxxxxxxxxx xxxxxxx jakýmkoliv xxxxxxx zdravotnickým regulačním xxxxxx (xxxx. xxxxxx x preklinickém xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx drogy, xxxxxxxxxxx xxxx), xx xxxxxxxx xxxxx.
S1. XXXXXXXXXX XXXXX
Xxxxxxxxxx xxxxx jsou xxxxxxxx.
1. ANDROGENNÍ ANABOLICKÉ XXXXXXXX (XXX):
(a) Xxxxxxxx* XXX, zahrnující:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; boldenon; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); desoxymethyltestosteron (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); drostanolon; ethylestrenol (19-xxx-17α-xxxxx-4-xx-17-xx); fluoxymesteron; formebolon; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9-dien-3-on); xxxxxx-1-xxxxxxxxxxx (17β-hydroxy-17α-methyl-5α-androst-1-en-3-on); methylnortestosteron (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); methyltestosteron; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-norandrostendion (estr-4-en-3,17-dion); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-homo-pregna-4,9,11-trien-17β-ol-3-on); xxxxxxxxx x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** XXX, pokud xxxx xxxxxx xxxxxxxx:
Xxxxxxxxxxxxx (androst-5-en-3β,17β-diol), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, prasteron (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xxx), xxxxxxxxxxx x xxxxxx xxxxxxxxxx x xxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx:
| &xxxx;
5α-xxxxxxxxx-3α,17α-xxxx
|
&xxxx;
5-xxxxxxxxxxxxx (androst-5-en-3,17-dion)
|
|
5α-androstan-3α,17β-diol
|
|
|
5α-androstan-3β,17α-diol
|
epi-dihydrotestosteron
|
|
5α-androstan-3β,17β-diol
|
epitestosteron
|
|
androst-4-en-3α,17α-diol
|
3α-hydroxy-5αandrostan-17-on
|
|
androst-4-en-3α,17β-diol
|
3β-hydroxy-5αandrostan-17-on
|
|
androst-5-en-3β,17α-diol
|
7α-hydroxy-DHEA
|
|
androst-5-en-3α,17α-diol
|
7β-hydroxy-DHEA
|
|
androst-5-en-3α,17β-dioI
|
7-keto-DHEA
|
|
androst-5-en-3β,17α-diol
|
19-norandrosteron
|
|
4-androstendiol (xxxxxxx-4-xx-3β,17β-xxxx)
|
&xxxx;
19-xxxxxxxxxxxxxxxxx
|
2. Xxxxxxx anabolické xxxxx, zahrnující:
Xxxxxxxxxxx, xxxxxxxxxx modulátory androgenových xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
| &xxxx;
Xxx xxxxx xxxxxxx xxxx xxxxx: * "exogenní" xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxx xxxxxxxx xxxxxxx xxxxxxxxxx přirozeně. ** "xxxxxxxxx " se xxxxxxxx x xxxxx, xxxxxx může xxxx xxxxxxxxxx xxxxxxxxx.
|
X2. PEPTIDOVÉ XXXXXXX, XXXXXXX XXXXXXX A XXXXXXXX XXXXX
Následující xxxxx x xxxxxx xxxxxxxxxx faktory xxxx xxxxxxxx:
1. Látky xxxxxxxxxxx xxxxxxxxxxx (např. xxxxxxxxxxxx (XXX), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx beta (CERA), xxxxxxxxxxx /Hematide/);
2. Xxxxxxxxxxxxxxxxxx (CG) x Xxxxxxxxxxxx xxxxxx (LH) x xxxx;
3. Xxxxxxxxxxxxxx;
4. Xxxxxxx xxxxxx (GH), fibroblastové xxxxxxx xxxxxxx (FGFs), xxxxxxxxxxxx xxxxxxx faktor (XXX), xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (XXX-1), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), růstový faktor xxxxxxxx x xxxxxxxx xxxxxxxx (PDGF) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), xxxxxx xxxx xxxxxxxxx xxxx xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx xxxx degradaci xxxxxxxx xxxxx, šlach x xxxxxx, krevní xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx nebo ovlivňující xxxx svalových vláken;
x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.
S3. XXXX2- XXXXXXXX
Všichni xxxx-2 xxxxxxxx včetně xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. x- x x-), xxxx xxxxxxxx xxxxx salbutamolu (xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx), xxxxxxxxxxx (maximálně 36 xxxxxxxxxx za 24 xxxxx) x xxxxxxxxxxx xxxxx xxxx xxxxxx x xxxxxxxx v xxxxxxx s xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx.
Xxxxxxxxxx xxxxxxxxxxx v xxxx v xxxxxxxxxxx xxxxx xxx 1000 xx/xx a xxxxxxxxxx xxxxxxxxxxx v xxxx x xxxxxxxxxxx vyšší xxx 40 xx/xx xxxxxx považována xx xxxxxxxxx terapeutické xxxxxxx, xxx xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx sportovec xxxxxxxxx kontrolovanou xxxxxxxxxxxxxxxxx xxxxxx, že xxxxxxxxxx xxxxxxxx byl xxxxxxxx xxxxxxxx xxxxxxxxxxxx inhalační xxxxx xxxxx než xxxx xxxxxxx xxxxxxx.
X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx následující:
1. Xxxxxxxxxx aromatáz, zahrnující:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx),xxxxxxxxx, xxxxxxxxx, letrozol, xxxxxxxxxxx, xxx ne x xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx xxxxxxxxxx estrogenových xxxxxxxxx (XXXX), zahrnující:
Xxxxxxxxx, xxxxxxxxx, toremifen, xxx xx x omezením xxxxx xx xx.
3. Xxxxxxx antiestrogenní xxxxx xxxxxxxxxx:
Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx myostatinu, ale xx x xxxxxxxx xxxxx xx xx.
5. Xxxxxxxxxxx xxxxxxxxxx:
x) Xxxxxxxx;
x) Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Receptor δ (PPARδ) agonists/ (xxxx. XX 1516) x Xxxxxxxx proteinkinasové xxx xxxxxxxxxx XXX x součinnosti s XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx xxxxxx (AMPK) xxxx xxxxxxxx/ (xxxx. XXXXX)
X5. DIURETIKA X XXXXXXX XXXXXXXXX XXXXX
Xxxxxxxxx xxxxx xxxx xxxxxxxx. Xxxxxxxx:
Xxxxxxxxx, xxxxxxxxxxxx, plasmaexpandery (xxxx. glycerol, xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx a mannitolu), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx. Lokální xxxxxx felypressinu pro xxxxx xxxxxxxx není xxxxxxxx.
Xxxxxxxxx zahrnují:
Xxxxxxxxxxxx, amilorid, bumetanid, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, kyselina xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, thiazidy (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), triamteren a xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx podobnými xxxxxxxxxxxx xxxxxx (kromě xxxxxxxxxxxx, xxxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxxxx a xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).
Xxx použití (Xxx Xxxxxxx, xxxxxxxx Xxxx Xxxxxx) jakéhokoliv xxxxxxxx xxxxx xx xxxxxxxxxx prahovým xxxxxxx (xx. formoterol, xxxxxxxxxx, xxxxxx, katin, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx xxxxxxx s xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx xx xxxx xxxxx navíc x té, xxxxx xxx xxxx xxxxxxx xx diuretikum nebo xxxxx xxxxxxxxx xxxxx.
XXXXXXXX XXXXXX
X1. XXXXXXXXXX X XXXX X XXXXXXXX KOMPONENTAMI
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxx nebo xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx x xxx xxxxxxxxx produktů xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx.
2. Xxxxx xxxxxxxxx spotřeby, xxxxxxx nebo dodávky xxxxxxx, xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (např.krevní xxxxxxxx xxxxxxxx xx xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx a xxxxxxxxxxx (XXX13), ale xx x xxxxxxxx xxxxx xx xx. Suplementace xxxxxxxx xxxxxxxx xxxx.
3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx x xxxxxxxx komponentami xxxxxxxxxxx xxxx chemickými způsoby.
X2. XXXXXXXX A XXXXXXXXX MANIPULACE
Xxxxxxxx xx následující:
1. Xxxxxxxxx, nebo xxxxx x xxxxxx, za xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx xx xxxxxxxx. Xx xxxxxxxx záměnu x/xxxx xxxxxx (xxxx. xxxxxxxxxx) moči, xxx xx x xxxxxxxx xxxxx na xx.
2. Nitrožilní xxxxxx x/xxxx xxxxxxx xxxx xxx 50 xx xx 6 xxxxx xxxx xxxxxxxx kromě xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.
X3. XXXXXX XXXXXX
X xxxxxx potenciálu xx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx následující:
1. Transfer xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Použití xxxxxxxxxx xxxx geneticky xxxxxxxxxxxxxx xxxxx;
| &xxxx;
XXXXX X METODY XXXXXXXX XXX XXXXXXX
|
Xxxxx xxxxxxxxx X0 xx S5 a X1 xx X3 xxxxxxxxx xxxx xxxx Xxx Xxxxxxx xxxxxxxx x následující skupiny:
XXXXXXXX XXXXX
S6. XXXXXXXXXXX
Xxxxxxx xxxxxxxxxxx xxxxxx xxxxx jejich xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. d- x x-) jsou zakázaná, x výjimkou xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx použití x xxxxxxxxxxx zahrnutých xx Monitorovacího programu xxx xxx 2013*.
Xxxxxxxxxxx xxxxxxxx:
(x) Xxxxxxxxxxxx stimulancia:
Adrafinil, xxxxxxxxxx, amfetaminil, amfetamin, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, bromantan, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, famprofazon, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (karfedon), xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, mefenorex, mefentermin, xxxxxxxxxxxx (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, prenylamin, xxxxxxxxx.
Xxxxxxxxxxxx, které xxxx výslovně uvedeno x xxxxx odstavci, xx Specifickou xxxxxx.
(x) Xxxxxxxxxx xxxxxxxxxxx (xxxxxxxx):
Xxxxxxxxx**, katin***, xxxxxxx****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, fenprometamin, xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, pentetrazol, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, sibutramin, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx látky x xxxxxxxx chemickou strukturou xxxx xxxxxxxxx biologickými xxxxxx.
* Xxxxxxxxxxx xxxxx zahrnuté do Xxxxxxxxxxxxxx xxxxxxxx 2013 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, nikotin, xxxxxxxxx, xxxxxxxx) xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.
** Xxxxxxx xxxxxx xxxxxxxxxx (xxxx. nosní, xxxx xxxxxxxx) xxxx xxxx podání xxxxxxxx x lokálními xxxxxxxxxx xxxx zakázáno.
*** Xxxxx xx xxxxxxxx xxxxx při koncentraci xxxxx než 5 xxxxxxxxxx v 1 xx moči.
**** Xxxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxx při xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx xxxx.
***** Xxxxxxxxxxxxx je xxxxxxx, pokud jeho xxxxxxxxxxx v xxxx xx xxxxx xxx 150 xxxxxxxxxx xx xxxxxxxx
X7. XXXXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx a xxxx xxxxxxxx, hydromorfon, xxxxxxx, xxxxxx, xxxxxxxx, oxymorfon, xxxxxxxxxx, petidin.
X8. XXXXXXXXXXX
Xxxxxxxx (xxxx. xxxxx, xxxxxx x xxxxxxxxx) xxxx syntetický xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) a xxxxxxxxxxxxxx (xxxx. "Spice" /XXX018, JWH073/ x XX-210) xxxx zakázané.
X9. XXXXXXXXXXXXXXXXXXXX
Všechny xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.
| &xxxx;
XXXXX ZAKÁZANÉ X XXXXXXXX XXXXXXXX
|
X1. XXXXXXX
Xxxxxxx (xxxxxx) xx xxxxxxxx xxxxx Xxx Xxxxxxx v následujících xxxxxxxx. Xxxxxxx se xxxx xxxxxxxx dechovou xxxxxxxx x/xxxx rozborem xxxx. Prahová xxxxxxx xxx porušeni xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx hodnota) xx 0.10 x/x.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx a parašutismus(FAI)
∙ Xxxxxxxxxxx (FITA)
∙ Motocyklový xxxxx (XXX)
∙ Vodní xxxxxxxxxx (UIM)
P2. XXXX-XXXXXXXXX
Xxxxx xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx pouze Xxx Xxxxxxx v xxxxxxxxxxxxx xxxxxxxx.
∙ Xxxxxxxxxxxx sport (XXX)
∙ Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
∙ Xxxx (XXX)
∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx také Xxxx xxxxxx)
∙ Xxxxxxxx (XXX) - skoky xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx a X-xxxxx,x snowboard X-xxxxx x "big xxx"
∙ Xxxxxxx (XXXX, XXX) (xxxxxxxx také Xxxx soutěž)
∙ Xxxxx (XXX)
Beta-blokátory xxxxxxxx následující látky:
Xxxxxxxxxx, alprenolol, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, bunolol, xxxxxxxxxx, esmolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, timolol, xxx xx s xxxxxxxx xxxxx na ně.
Informace
Xxxxxx xxxxxxx č. 98/2013 Sb. x. x. xxxxx xxxxxxxxx xxxx 20.12.2013.
Xxxxxx xxxxxxx č. 98/2013 Xx. x. x. xxx xxxxxx právním xxxxxxxxx č. 47/2014 Sb. m. s. s xxxxxxxxx xx 20.9.2014.
Xxxxx xxxxxxxxxxxx xxxxxxxx norem jiných xxxxxxxx xxxxxxxx x xxxxxxxx xxxx aktualizováno, xxxxx se jich xxxxxx xxxxxxxxx změna xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.